MobiHealthNews

Bayer gets FDA nod for app-connected injector for MS patients

Bayer recently received FDA approval for a connected auto-injector for relapsing-remitting multiple sclerosis medication and companion app. The device is called the Betaconnect Electronic Autoinjector ...
Healio

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...
WebMD

Managing Multiple Sclerosis With Kesimpta: What You Need to Know

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...
Nasdaq

FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...
Benzinga.com

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion

Roche Holdings AG's (OTC:RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...
The American Journal of Managed Care

Subcutaneous Ofatumumab Shows Reduced Injection Reactions in Multiple Sclerosis

New findings show a similar number of injective-related reactions (IRRs) were reported between the use of ofatumumab (Kesimpta) and ocrelizumab (Ocrevus) in the treatment of multiple sclerosis, but ...
Morningstar

ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...
Nasdaq

US FDA declines to approve Viatris's injection for multiple sclerosis

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris VTRS.O and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.
manilatimes

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE)-- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...